Navigation Links
Multiple myeloma patients experience high response rate with new 3-drug combination
Date:12/5/2009

NEW ORLEANSA new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

Partial responses or better were seen in all of the 66 patients treated with the drug combination in the multi-center study, with 74 percent having a "very good partial response rate" in the phase 2 population, reports Paul G. Richardson, MD, of Dana-Farber, who led the study. The rate of complete or "near complete" responses to the therapy was also encouraging at 54 percent.

Richardson will describe the results in an oral presentation at the American Society of Hematology's 51st annual meeting on Saturday, Dec. 5 (Abstract 1218, Ernest N. Morial Convention Center, Hall E, 5:30-7:30 pm CT).

The regimen, known as RVD, combined the drugs Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone, which previously were found to be highly effective in multiple myeloma patients who had relapsed or no longer responded to first-line therapies.

Fifteen of the 35 newly diagnosed patients in the open-label phase 2 portion of the study subsequently underwent autologous (using their own blood-forming stem cells) transplants, a standard treatment for multiple myeloma "and did very well," says Richardson.

For the entire group, after a median 19.3 months of follow up, the median time-to-progression (TTP) of the disease, progression-free survival (PFS), and overall survival (OS) had not yet been reached, according to the presentation. The estimated TTP and PFS at one year are 76 percent, and the estimated one-year overall survival is 100 percent, the results showed.

An estimated 20,580 new cases of multiple myeloma will be diagnosed in 2009, according to the American Cancer Society, and 10,580 patients will die from the disease.

Richardson says it was "particularly exciting" to observe that the high response rate was not affected by the specific genetic characteristics of the patients' disease. Patients with so-called "adverse cytogenetics" are at higher risk for treatment failure and death, but in the current study the drug combination worked as well for them as it did in patients with more favorable cytogenetic features.

The toxic side effects of the treatment were "manageable," Richard says. The main adverse effect was peripheral neuropathy (numbness or pain in the extremities), which typically cleared up after dosages were lowered and the treatment was completed.

"Our conclusion is that this is a highly effective regimen for newly diagnosed multiple myeloma patients," says Richardson. "The combination has now gone into large phase 3 clinical trials, and we think it has the potential to be a new standard of treatment in multiple myeloma."


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Timing of Multiple-Ligament Knee Surgery May Not Matter
2. Childbirth May Slow Progression of Multiple Sclerosis
3. Multiple Health Conditions Discovered During Free Clinic for Uninsured People in New Orleans
4. Patient Advocate Foundation Announces Additional Support for Co-Pay Relief Program Serving Multiple Myeloma Patients
5. Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy
6. Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries
7. New IVF Guidelines Aim to Reduce Multiple Births
8. Gentle touch may aid multiple sclerosis patients
9. People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life
10. Early Drug Treatment May Cut Multiple Sclerosis Risk
11. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) officials today announced a ... the Network’s programs and services in the greater Pittsburgh region. Starting January 23, patients ... offered one for that same afternoon. , AHN is the first ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... asset protection and financial planning services to communities throughout eastern Georgia, is embarking ... against heart disease. , Heart disease kills more Americans every year than anything ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or ...
(Date:1/19/2017)... ... ... Attorney Robert “RC” Pate , founder of The Law Office of ... Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. In 2006, ... of the critical funding gap for research into pediatric cancer research. From 2006 onwards, ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second ... Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. ... have each been chosen by their peers for the 2017 list based on ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, ... The global anti-obesity drugs market is expected ... of the forecast period and CAGR of 38.7% in the second ... at a CAGR of 32.8% from 2016 to 2027. The market ... and $24,063 million in 2027. ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 Accuray ... its CyberKnife® and TomoTherapy® Systems continue to set the ... received the highest composite overall user satisfaction rating among ... the Q4 2016 MD Buyline Market Intelligence Briefing™. The ... the highest composite ratings among industry peers for 11 ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: